Table 7.
Melanomas. Adjuvant treatment with vaccines. Randomised studies [20].
| Authors | No. of cases | Stage | Treatment | Followup (years) | Statistical significance |
|---|---|---|---|---|---|
| Livingston 1994 | 123 | III | GM2 + BCG + CFM | 5 y. | NS |
| BCG + CFM | |||||
| Wallack 1995 | 250 | II | Virus allogeneic polyvalent melanoma cell lysate | 2.5 y. | NS |
| Wallack 1998 | 250 | III | Melanoma cell lysate vaccine | 3 y. | NS |
| Bystryn 2001 | 38 | III | Polyvalent shed antigen | 2.5 y. | S |
| Placebo | |||||
| Sondak 2002 | 689 | IIA | Melacine and DETOX | 5.6 y. | NS |
| Observation | |||||
| Hershey | 700 | IIB | Cell lysate vaccine | 8 y. | Tendency in RFS/GS |
| Placebo |